Articles tagged with Alzheimer Disease
A new study suggests that the brain uses a mechanism called 'repulsion' to differentiate between similar environments. Researchers found that when participants were asked about stores shared between two cities, their brains showed surprisingly different patterns of activity, indicating that they were treating these familiar locations a...
A new nasal vaccine, Protollin, is being tested in humans for the first time to prevent and slow Alzheimer's disease progression. The trial aims to determine safety and tolerability, as well as its effects on the immune system.
Researchers have identified thousands of novel brain-expressed gene isoforms, revealing a complex web of protein production in the brain. The study suggests that genes expressed in the brain may produce far more proteins than previously thought, with potential implications for diseases such as Alzheimer's and schizophrenia.
A study published in Brain Pathology found elevated levels of tau protein in the brains of people with ALS who carry a mutation in the C9orf72 gene. The researchers also identified new genetic mutations in the tau gene and discovered that the ratio of different forms of tau protein may be an indicator of disease progression.
A phase 2 clinical trial found that losartan, commonly used to treat high blood pressure, did not significantly slow down the progression of Alzheimer's disease in people with mild-to-moderate symptoms. However, the drug may still be beneficial for those with early-stage disease if prescribed for longer periods.
A study published by Sanford Burnham Prebys found unappreciated changes in brain cell types involving hundreds of thousands of never-before-seen RNAs in individuals with Down syndrome. This breakthrough provides new avenues for understanding both Down syndrome and Alzheimer's disease.
Researchers have discovered a promising new treatment and vaccine for Alzheimer's disease by targeting the toxic form of amyloid beta protein. Both the antibody-based treatment and the protein-based vaccine reduced Alzheimer's symptoms in mouse models, offering hope for potential transformation in patient lives.
Researchers at Massachusetts General Hospital discovered that reducing abnormal tau can reverse mitochondrial dysfunction and oxidative stress in ALS. By targeting tau with a specific degrader, the study suggests a promising new treatment strategy for this degenerative disease.
Researchers at the University of Toronto have demonstrated that listening to personally meaningful music induces beneficial brain plasticity in patients with mild cognitive impairment or early Alzheimer's disease. The study showed changes in neural pathways correlated with increased memory performance on neuropsychological tests, suppo...
A recent Rutgers University study found that receiving a new diagnosis of Alzheimer's disease and related dementias leads to decreased formal and informal social engagement. This can be particularly concerning for disadvantaged populations with limited resources. The study highlights the need for practitioners and policymakers to consi...
Researchers are modifying an arm of a worldwide clinical trial to evaluate a combination of drugs targeting two brain proteins: amyloid and tau. The Tau NexGen Trial aims to test the effectiveness of these treatments in slowing disease progression by targeting both Alzheimer's disease pathologies.
A meta-analysis of case-control and cohort studies found no causal link between H. pylori infection and Alzheimer's disease dementia, but may be associated with all-cause dementia. The study suggests future research on the pathogenic mechanism may lead to novel therapies.
A USF Health study reveals that fibrinogen can directly interact with neurons, leading to inflammation and neurodegeneration in Alzheimer's disease and traumatic brain injury. The researchers found that blocking the binding of fibrinogen to its receptors may alleviate short-term memory problems associated with these diseases.
A recent study published in Science Advances found that deleting the ABI3 gene increases amyloid-beta plaque accumulation and decreases microglia function, which may contribute to Alzheimer's disease progression. The researchers also identified a link between the mutation and increased risk of late-onset Alzheimer's.
Researchers have demonstrated the effectiveness of polymer-coated nanoparticles in delivering drugs to the brain, overcoming the blood-brain barrier challenge. The study showed that zwitterionic polymers improve accessibility but are rapidly absorbed by blood vessel walls.
Researchers found that glatiramer acetate improved cognitive behavior and reduced amyloid plaques in a mouse model of Alzheimer's disease. This study suggests therapies targeting the immune system could be effective in treating the disease.
A new study suggests that greater cumulative estrogen exposure in life may counter the brain-shrinking effect of menopause. Women with longer reproductive years, more children, and hormone therapy showed increased gray matter volume in certain brain areas. This protective effect may help reduce Alzheimer's risk in women.
In a mouse model of Alzheimer's disease, researchers found that restoring normal sleep reduced amyloid-beta plaque accumulation. The thalamic reticular nucleus played a previously unsuspected role in symptoms associated with Alzheimer's, and its restoration could be a potential therapeutic approach.
Researchers identified a gene family called MEF2 that controls a genetic program promoting resistance to cognitive decline. Enriching activities appear to activate MEF2, which may help prevent age-related dementia.
Recent research highlights microglia's involvement in Alzheimer's development and progression. A better understanding of microglial dysfunction may help explore signs and mechanisms of the disease, as well as enable microglia as a potential therapeutic target.
Hyperbaric oxygen therapy alleviated cognitive dysfunction, improved cerebral blood flow, and reduced amyloid burden in Alzheimer's disease models. In elderly patients with significant memory loss, HBOT showed an increase in cerebral blood flow and improvement in cognitive performance, demonstrating its therapeutic effects.
Aging-US review highlights cerebrovascular dysfunctions as a core feature of AD, contributing to pathogenesis and progression. Adrenergic system modulation may serve as a key approach to modulate these abnormalities.
Recent findings highlight the prevalence of cerebrovascular disorders in AD patients and suggest that cerebral vascular alterations contribute to pathogenesis. The adrenergic system may serve as a key approach to modulate these abnormalities and progressive neurodegeneration.
Researchers found that Alzheimer's disease develops by replicating aggregates in individual brain regions, rather than spreading them. The study used human data and PET scans to track the aggregation of tau protein, a key player in the disease.
Researchers at UTSW Medical Center discovered a way to abolish the formation of amyloid beta plaques in a mouse model of Alzheimer's disease by inhibiting the NHE6 gene. This breakthrough suggests a possible treatment approach for preventing late-onset Alzheimer's, a condition affecting nearly 6 million Americans.
Researchers developed a new NMR spectroscopic method to map IDP function more easily, fast, and accurately. The method sheds light on mechanisms of diseases like Parkinson's, Alzheimer's, and type 2 diabetes.
A new study from the University of Eastern Finland found that working-age people living with dementia experience insufficient guidance and counselling. This results in premature retirement and loss of social contacts, leading to feelings of anxiety, exhaustion, and shame.
Researchers have found four commonly used medications that can reverse Alzheimer's disease in mice by addressing the underlying causes of the condition. The study identifies non-steroidal anti-inflammatories and anti-hypertensives as effective treatments, paving the way for early diagnosis and potential therapy.
A study by Florida Atlantic University found that robotic pet cats improved mood scores and cognitive function in adults with mild to moderate dementia. The intervention involved 12 visits with the robotic cat, where participants interacted with it and reported positive emotions.
Scientists at Gladstone Institutes discovered that non-convulsive epileptic activity drives chronic brain inflammation in Alzheimer's models, which can be reversed by eliminating protein tau or using the anti-epileptic drug levetiracetam. This link between brain networks and immune cells may hold promising treatments for Alzheimer's di...
A new study found that retired male elite rugby union players aged 50+ who suffered three or more rugby-related concussions during their career have no worse average cognitive function than those with no, one, or two concussions. However, over-75s with a history of multiple concussions showed significantly worse cognitive function on a...
A multi-year study found that both short and long sleepers experience greater cognitive decline than those who slept a moderate amount. Researchers separated out the effects of poor sleep and Alzheimer's disease on cognition, suggesting a middle range or 'sweet spot' for total sleep time where cognitive performance is stable over time....
Researchers at GIST create an optical technique called optical speckle image velocimetry that can image dynamic changes in cerebral blood flow, allowing for the diagnosis of brain health. The technique provides high-time resolution and measures both speed and direction of blood flow.
Researchers at Gladstone Institutes found that reducing tau levels impacts both excitatory and inhibitory cells, leading to a reduction in excitation-inhibition ratios. This effect counteracts diseases that cause abnormal increases in this ratio, potentially improving the brain's ability to perform its functions.
DZNE researchers found that viral molecules facilitate the intercellular spreading of protein aggregates, which are hallmarks of brain diseases like Alzheimer's. The presence of viral ligands increases protein aggregate spreading between cells, potentially contributing to neurodegeneration.
A pilot study found improvements in memory, motor function, and processing skills in healthy individuals after receiving transcranial photobiomodulation therapy. The therapy, involving infrared light, has the potential to alleviate nerve cell damage and reduce symptoms of dementia.
Microglia play a vital support role in maintaining blood vessels in the brain, regulating blood flow and capillary diameter. This discovery may lead to new therapies for diseases affecting small brain vessels, such as Alzheimer's and stroke.
Michel Goedert's research focuses on protein aggregates in Alzheimer's and Parkinson's, providing deep insights into disease development. His work is essential for finding new treatments, as evidenced by his discovery of gene mutations leading to dementia.
A special collection of articles reviews the application of photobiomodulation therapy for dementia, Alzheimer's disease, and other brain conditions. The therapy has been shown to promote microcirculation, cellular proliferation, and regeneration, reducing pain, inflammation, and oxidative stress.
Researchers identify key neurons and signaling pathway regulating female activity before ovulation. Discoveries could lead to new treatments for menopause that sidestep estrogen and reactivates the circuit with CRISPRa technology.
Researchers found that personality traits such as neuroticism and conscientiousness are associated with changes in the brain linked to Alzheimer's disease. In cognitively normal individuals, higher neuroticism and lower conscientiousness were linked to increased amyloid and tau deposits.
Researchers discovered that bumetanide, a 30-year-old diuretic, reverses signs of Alzheimer's disease in mice and human brain cells. The study also found that people over 65 who took bumetanide were less likely to develop Alzheimer's disease.
Researchers found an early indicator of Alzheimer's disease is an oxidation-antioxidant imbalance in the blood. Oxidative markers increase up to five years before the onset of the disease, suggesting a potential avenue for prevention through antioxidant intake.
A study found that people with an Alzheimer's gene mutation have disrupted white matter integrity, which may predict the onset of dementia. The researchers used advanced MRI techniques to compare carriers and non-carriers, finding lower structural connectivity in the frontoparietal control network.
Research associates gray matter and white matter neurodegeneration with subjective cognitive complaints, highlighting potential non-AD pathologies. Neurodegeneration processes affect brain areas not typically targeted by Alzheimer's disease.
A commonly used diuretic pill may help treat Alzheimer's disease in individuals with the apolipoprotein E gene APOE4. Researchers analyzed data from brain tissue samples and found that those taking bumetanide had a significantly lower prevalence of Alzheimer's disease compared to those not taking the drug.
The USC Stevens INI is partnering with Vanderbilt University Medical Center and the University of Miami to merge Alzheimer's disease data from over 30 datasets, producing a large-scale, standardized set of clearly defined data. This harmonization will enable large-scale machine learning analysis to better characterize the genetic basis...
Researchers found a chemical inhibitor of PDE9 stimulates cells to burn more fat in mice, reducing obesity and fatty liver. The study's findings suggest the experimental drug may be effective in treating severe obesity and improving heart function.
A UCL-led research team has identified an anti-viral gene that increases the risk of both Alzheimer's disease and severe Covid-19. The study found that a specific variant of the OAS1 gene amplifies inflammation in the brain, highlighting the importance of the immune system in both conditions.
A new study found that toxic fatty acids produced by astrocytes can trigger cell death in damaged neurons, which may contribute to neurodegenerative diseases such as glaucoma and Alzheimer's. Blocking the production of these fatty acids in mice preserved 75% of neurons, suggesting a promising target for treatment.
Scientists have developed an improved technique to trace brain connections between neurons in zebrafish using vesicular stomatitis virus (VSV), enabling the visualization of connected neurons up to five days after infection. This breakthrough could provide insights into brain network connectivity repair after injury or disease.
Research investigates m6A regulators in cognitive dysfunctions, identifying potential biomarkers like SNRPG and SNRPD2. The study also highlights the role of APOE ε4 allele and FTO expression in AD development.
Researchers will investigate hidden signs of brain damage in REM behavior disorder, aiming to identify biomarkers that predict impending neurological disease. The goal is to delay the onset or prevent dementia or Parkinsonism through clinical trials.
A study by University of South Florida Health researchers suggests that fenchol, a natural compound in basil, can help reduce neurotoxic amyloid-beta in the brain. Fenchol stimulates FFAR2 signaling, reducing senescent neuronal cells and increasing Aβ degradation.
Researchers found that a cancer chemotherapy drug can restore memory and cognitive function in mice with Alzheimer’s disease by inhibiting blood vessel growth. The study suggests repurposing approved anti-cancer drugs as treatments for Alzheimer’s disease, potentially shortening clinical development time.
The study found no significant causal relationship between genetically determined age at menarche or menopause and AD risk. However, an inverse association was detected between age at menarche and body mass index. Further studies are needed to validate these findings.
Researchers at Uppsala University have designed new antibodies that bind to both large and small aggregates of the amyloid-beta protein, potentially providing a more effective treatment for Alzheimer's disease. The new antibody format is stronger in binding to clumps and can also target smaller aggregates.
Researchers found that early accumulation of tau proteins in the brain, measured by PET scanner, is more effective at predicting memory impairment than other biomarkers. The study suggests that tau PET should be recommended for clinical prognostic assessment of cognitive decline in Alzheimer's patients.
Researchers found that vitamin B12 supplementation improved movement in worms with Alzheimer's-like symptoms, suggesting a potential link between diet and disease progression. The team also discovered that vitamin B12 relies on an enzyme called methionine synthase to work, and its effects are limited to those with dietary deficiencies.
The Buck Institute has been awarded a $14.3 million grant from the NIH to study cellular senescence, a hallmark of aging, as a driver of Alzheimer's disease and other age-related dementias. Researchers will investigate new mechanisms that can be developed into interventions to treat patients.